FDA/CMS Gene Editing Guidance Shifts Evidence to CMC Teams

On October 27, 2026, the FDA issued draft guidance, describing how sponsors can submit and manage biologics license applications (BLAs) for individualized genome editing products for rare genetic diseases.¹ The document, “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management,” addresses how a single license can cover therapies whose design differs from patient to patient. The CMS paired the announcement with plans to expand its Cell and Gene Therapy Access Model beyond sickle cell disease.

What is the Individualized Feature Space?

Central to the guidance is the Individualized Feature Space (IFS), a predefined set of boundaries describing how a product may vary between patients while remaining within one BLA.¹According to the FDA, when a new patient-specific variant falls within the IFS and assays show adequate safety and activity, the sponsor can add it to the BLA through a streamlined review. That review relies on the clinical trials supporting the original approval, plus in vitro data for the new variant, rather than on additional trials. The draft also covers manufacturing, safety testing, including the risk of unintended genetic changes, and naming and labeling.

“This guidance represents a critical step forward in FDA’s efforts to support the development of individualized therapies for patients with rare genetic diseases,” said Karim Mikhail, director, CBER, in a press release.¹ “By providing a clear and scientifically rigorous framework for BLA submission and postapproval management, we are helping to ensure that patients—including those with ultrarare conditions for whom no treatment currently exists—can more efficiently access therapies that may be life-changing.”

Why Does this Development Matter?

The IFS shifts much of the evidentiary burden for new variants from clinical data to analytical and process data.¹ Assays characterizing on-target editing and off-target activity will carry substantial regulatory weight, as will evidence that the platform process performs consistently as patient-specific components change. Defining IFS boundaries is likely to become a CMC decision as much as a clinical one. Boundaries drawn too narrowly limit how many patients a license can serve, while boundaries drawn too broadly may be difficult to support with characterization data.

The guidance builds on the Plausible Mechanism Framework, which allows for a well-supported mechanism of action to serve as the basis for adding variants that target mutations not studied in an initial trial.¹ The guidance also aligns with the FDA’s Rare Disease Framework Initiative that brings risk-based CMC review and preapproval inspections into scope for sponsors and contract manufacturers.

How will CMS Approach Access?

Under the voluntary model, CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs.¹ The model’s first evaluation found that pooling beneficiaries eased states’ administrative burden and strengthened their negotiating leverage. In the coming months, CMS will release a request for applications inviting manufacturers of therapies for other conditions to participate, including manufacturers of therapies that are already approved. The goal is to start negotiations sooner after FDA approval or licensure.

FDA is accepting comments under docket FDA-2026-D-11783 at regulations.gov for 30 days following publication in the Federal Register.

What Off-Target Data Could Support Each New Variant?

An April 2026 FDA draft guidance on sequencing-based safety assessment of genome editing products outlines what that analytical evidence may involve.² The FDA recommends off-target studies use the editor proposed for the final product, cells representative of the target tissue, and on-target editing rates comparable to those in the drug product, with unedited and edited control pairs. Analysis accounting for human genetic variation may be unnecessary for ultrarare or single-patient indications. However, major manufacturing changes affecting editor activity could require additional off-target analysis, and sponsors may need to submit raw sequencing data and analysis scripts with a BLA.

References

1. US Department of Health and Human Services. FDA and CMS announce new steps to advance gene therapies and expand access for patients with rare diseases. October 27, 2026. Accessed October 28, 2026. View source

2. FDA. Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing: Draft Guidance for Industry. April 2026. Accessed October 28, 2026. View source